Schrödinger, Inc. (SDGR)

NASDAQ: SDGR · Real-Time Price · USD
20.60
+0.25 (1.23%)
At close: Jun 24, 2025, 4:00 PM
20.63
+0.03 (0.15%)
After-hours: Jun 24, 2025, 7:28 PM EDT
1.23%
Market Cap 1.51B
Revenue (ttm) 230.49M
Net Income (ttm) -192.21M
Shares Out 73.38M
EPS (ttm) -2.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 875,454
Open 20.70
Previous Close 20.35
Day's Range 20.15 - 20.88
52-Week Range 16.60 - 28.47
Beta 1.62
Analysts Buy
Price Target 32.80 (+59.22%)
Earnings Date Jul 30, 2025

About SDGR

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration an... [Read more]

Sector Healthcare
IPO Date Feb 6, 2020
Employees 891
Stock Exchange NASDAQ
Ticker Symbol SDGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price forecast is $32.8, which is an increase of 59.22% from the latest price.

Price Target
$32.8
(59.22% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 13, 2025, the company granted restricted stock units (RSUs) with respect to 10,290 shares of the company's commo...

7 days ago - Business Wire

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Schrödinger's SGR-1505 Phase 1 data shows encouraging safety and niche efficacy, especially in BTKi-resistant Waldenström macroglobulinemia patients. Despite a headline 22% ORR, the nuanced data suppo...

11 days ago - Seeking Alpha

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

MILAN--(BUSINESS WIRE)--Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.

12 days ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

18 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

19 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

20 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

21 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

22 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

23 days ago - Accesswire

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

25 days ago - Accesswire

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company's newly appointed EVP, Chief Commercial Officer, Global Head of Softwar...

26 days ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

26 days ago - Accesswire

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial off...

26 days ago - Business Wire

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

27 days ago - CNBC Television

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

4 weeks ago - Accesswire

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

4 weeks ago - Accesswire

Schrödinger to Present at Jefferies Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation wil...

4 weeks ago - Business Wire

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

Schrödinger delivered strong Q1 results, with robust software growth and improving margins, despite a tough macro environment. Regulatory changes, especially the FDA's move away from animal testing, c...

5 weeks ago - Seeking Alpha

Schrödinger Announces CFO Appointment

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial off...

5 weeks ago - Business Wire

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hema...

5 weeks ago - Business Wire

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - ...

6 weeks ago - Seeking Alpha

Schrödinger Reports Strong First Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced financial results for the quarter ended March 31, 2025.

6 weeks ago - Business Wire